Top

Published in:

01-07-2011 | Original article

Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?

Authors: Sylvia Adams, Luba Greeder, Elsa Reich, Yongzhao Shao, Denise Fosina, Nicole Hanson, Jodie Tassello, Baljit Singh, Giulio C. Spagnoli, Sandra Demaria, Achim A. Jungbluth

Published in: Cancer Immunology, Immunotherapy | Issue 7/2011

Abstract

Introduction

Novel breast cancer risk-reducing strategies for individuals with germline mutations of the BRCA1 and/or BRCA2 genes are urgently needed. Identification of antigenic targets that are expressed in early cancers, but absent in normal breast epithelium of these high-risk individuals, could provide the basis for the development of effective immunoprophylactic strategies. Cancer testis (CT) antigens are potential candidates because their expression is restricted to tumors, and accumulating data suggest that they play important roles in cellular proliferation, stem cell function, and carcinogenesis. The objective of this study was to examine the expression of CT antigens and their frequency in BRCA-associated breast cancers.

Methods

Archived breast cancer tissues (n = 26) as well as morphologically normal breast tissues (n = 7) from women carrying deleterious BRCA 1 and/or 2 mutations were obtained for antigen expression analysis by immunohistochemistry. Expression of the following CT antigens was examined: MAGE-A1, MAGE-A3, MAGE-A4, MAGE-C1.CT7, NY-ESO-1, MAGE-C2/CT10, and GAGE.

Results

CT antigens were expressed in 16/26 (61.5%, 95% CI 43–80%) of BRCA-associated cancers, including in situ tumors. Thirteen of twenty-six (50%) breast cancers expressed two or more CT antigens; three cancers expressed all seven CT antigens. MAGE-A was expressed in 13/26 (50%) of cancers, NY-ESO-1 was expressed in 10/26 (38%) of tumors. In contrast, none of the CT antigens were expressed in adjacent or contralateral normal breast epithelium (P = 0.003).

Conclusions

We report a high CT antigen expression rate in BRCA-associated breast cancer as well as the lack of expression of these antigens in benign breast tissue of carriers, identifying CT antigens as potential vaccine targets for breast cancer prevention in these high-risk individuals.

Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329–1333PubMedCrossRef

Frost MH et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284(3):319–324PubMedCrossRef

van Oostrom I et al (2003) Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 21(20):3867–3874PubMedCrossRef

Michelsen TM, Dorum A, Dahl AA (2009) A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol 113(1):128–133PubMedCrossRef

Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28(2):222–231

Visvanathan K et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235–3258PubMedCrossRef

Finn OJ (2008) Cancer immunology. N Engl J Med 358(25):2704–2715PubMedCrossRef

Disis ML (2010) The ultimate in cancer chemoprevention: cancer vaccines. Cancer Prev Res (Phila) 3(4):406–409

Lollini PL et al (2006) Vaccines for tumour prevention. Nat Rev Cancer 6(3):204–216PubMedCrossRef

10.

Simpson AJ et al (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5(8):615–625PubMedCrossRef

11.

Valmori D et al (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104(21):8947–8952PubMedCrossRef

12.

Atanackovic D et al (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105(5):1650–1655PubMedCrossRef

13.

Jungbluth AA et al (2005) The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106(1):167–174PubMedCrossRef

14.

Cronwright G et al (2005) Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 65(6):2207–2215PubMedCrossRef

15.

Akers SN, Odunsi K, Karpf AR (2010) Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 6(5):717–732PubMedCrossRef

16.

Yawata T et al (2010) Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog 49(6):532–544PubMedCrossRef

17.

Gedye C et al (2009) Cancer/testis antigens can be immunological targets in clonogenic CD133 + melanoma cells. Cancer Immunol Immunother 58(10):1635–1646PubMedCrossRef

18.

Ajiro M et al (2009) Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol 35(4):673–681PubMed

19.

Cheever MA et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323–5337PubMedCrossRef

20.

Sugita Y et al (2004) NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 64(6):2199–2204PubMedCrossRef

21.

Taylor M et al (2007) Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res 9(4):R46

22.

Mischo A et al (2006) Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 118(3):696–703PubMedCrossRef

23.

Jungbluth AA et al (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99(6):839–845PubMedCrossRef

24.

Jungbluth AA et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92(6):856–860PubMedCrossRef

25.

Jungbluth AA et al (2000) Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 85(4):460–465PubMedCrossRef

26.

Theurillat JP et al (2007) NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8 + T-cell and CD79a + plasmacytic/B-cell infiltration. Int J Cancer 120(11):2411–2417PubMedCrossRef

27.

Otte M et al (2001) MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61(18):6682–6687PubMed

28.

Grigoriadis A et al (2009) CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 106(32):13493–13498PubMedCrossRef

29.

Kavalar R et al (2001) Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch 439(2):127–131PubMedCrossRef

30.

Curigliano G et al (2011) Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 22(1):98–103PubMed

31.

Anders CK, Carey LA (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9 (Suppl 2):S73–S81

32.

Aiyar SE et al (2007) Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells. Oncogene 26(18):2543–2553PubMedCrossRef

33.

Jazaeri AA et al (2004) BRCA1-mediated repression of select X chromosome genes. J Transl Med 2(1):32

34.

Jungbluth AA et al (2000) Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 83(4):493–497PubMedCrossRef

35.

Zhuang R et al (2006) Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun 6:7

36.

Kocher T et al (1995) Identification and intracellular location of MAGE-3 gene product. Cancer Res 55(11):2236–2239PubMed

37.

Robbins PF et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol

38.

Dhodapkar MV et al (2003) Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 3:9

39.

Rimoldi D et al (2000) Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 86(5):749–751PubMedCrossRef

40.

Landry C et al (2000) Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 86(6):835–841PubMedCrossRef

41.

De Plaen E et al (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40(5):360–369PubMedCrossRef

42.

Hudolin T et al (2006) Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 66(1):13–18PubMedCrossRef

43.

Velazquez EF et al (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)–correlation with prognostic factors. Cancer Immun 7:11

44.

Odunsi K et al (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63(18):6076–6083PubMed

45.

Brichard VG, Lejeune D (2008) Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther 8(7):951–968PubMedCrossRef

Title: Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?
Authors: Sylvia Adams
Luba Greeder
Elsa Reich
Yongzhao Shao
Denise Fosina
Nicole Hanson
Jodie Tassello
Baljit Singh
Giulio C. Spagnoli
Sandra Demaria
Achim A. Jungbluth
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1005-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2011

B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer

Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105

Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer